DirectorsTalk LSE Stock market news, financial, press release, articles and interviews
Tim McCarthy, Chairman of ImmuPharma PLC (LON:IMM) tells Proactive Investors they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.
Receive our exclusive interviews – Enter your email to stay up to date.
Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.
